Tirzepatide reset expectations for weight-loss medication, and retatrutide is now generating buzz as a possible next step. One is an approved, widely used drug. The other is still in clinical trials. Here is an honest comparison of where each stands and how they differ.
Quick Answer
Tirzepatide is an FDA-approved dual agonist that targets two gut hormone receptors (GIP and GLP-1), sold as Mounjaro and Zepbound. Retatrutide is an investigational triple agonist that adds a third target, the glucagon receptor, and is still in clinical trials, not yet approved. Early-phase trials of the drug class studied in retatrutide showed large weight loss, which is why it is closely watched, but it remains investigational. Today, tirzepatide is the available option; retatrutide is a future possibility pending trial results and approval.
Tirzepatide vs Retatrutide: What Is the Difference?
The headline difference is how many hormone pathways each drug hits.
Tirzepatide is a dual agonist. It activates the GLP-1 receptor and the GIP receptor. Hitting these two pathways amplifies appetite and metabolic effects, which is why tirzepatide produces strong weight loss.
Retatrutide is a triple agonist. It activates those same two receptors plus a third, the glucagon receptor. The glucagon component is thought to influence energy expenditure and fat metabolism, and the theory is that adding it could produce even greater weight loss. That third target is the core distinction.
The other major difference is status. Tirzepatide is approved and on the market. Retatrutide is investigational, still moving through clinical trials, and not available as an approved medication.
Is Retatrutide Better Than Tirzepatide?
It is too early to say definitively, and that nuance matters. Early-phase trials of the drug class studied in retatrutide produced large average weight loss, with the highest-dose groups reaching substantial reductions over the study period. Those results are why retatrutide has drawn so much attention.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →But there are real caveats. These are earlier-phase results, not the final, large-scale data that support full approval. Investigational drugs can look promising early and still face questions about long-term safety, durability, and real-world results. Until retatrutide completes its trial program and is reviewed by regulators, calling it "better" is premature. Tirzepatide, by contrast, has a completed approval-level evidence base and a real-world track record.
Tirzepatide vs Retatrutide Comparison Table
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Mechanism | Dual agonist (GIP, GLP-1) | Triple agonist (GIP, GLP-1, glucagon) |
| Status | FDA-approved (Mounjaro, Zepbound) | Investigational, in clinical trials |
| Availability | Available with prescription | Not yet approved or available |
| Evidence base | Completed approval-level trials | Earlier-phase (phase 2) trial data |
| Weight loss | Strong, well-documented | Large in early trials, still under study |
| Cost | Known pricing | Not commercially priced; not for sale |
What the Triple-Agonist Approach Adds
Researchers added the glucagon receptor because glucagon, beyond its role in blood sugar, is thought to influence how the body burns energy. The hope is that combining glucagon action with the appetite-suppressing GLP-1 and GIP effects could increase total weight loss. That is the scientific rationale for moving from dual to triple agonism. Whether it translates into a meaningfully better long-term treatment is exactly what ongoing trials are designed to determine.
Which Should You Consider?
Right now, the practical answer is tirzepatide, because it is the one you can actually be prescribed. Retatrutide is not available outside clinical trials. If you are choosing a treatment today, the real comparison is between tirzepatide and other approved medications. Retatrutide is worth knowing about as a development to watch, not as a current choice. Be cautious of any website selling "retatrutide," since it is not an approved product.
Frequently Asked Questions
What is the difference between tirzepatide and retatrutide?
Tirzepatide is an FDA-approved dual agonist (GIP and GLP-1). Retatrutide is an investigational triple agonist that adds the glucagon receptor and is still in trials.
Is retatrutide better than tirzepatide?
Early trials of the drug class studied in retatrutide showed large weight loss, but it is investigational and lacks final approval-level data, so it is too early to call it better.
Is retatrutide more effective than tirzepatide?
In early-phase data the highest doses produced large weight loss, but these are not head-to-head approval-level results, so a definitive comparison is not yet possible.
Is retatrutide approved by the FDA?
No. Retatrutide is investigational and remains in clinical trials. It is not available as an approved medication.
Is retatrutide more expensive than tirzepatide?
Retatrutide is not commercially sold, so it has no established price. Comparing cost is not yet meaningful.
What is a triple agonist?
A drug that activates three receptors at once. Retatrutide targets GIP, GLP-1, and glucagon receptors, versus tirzepatide's two.
Can I get retatrutide now?
Not as an approved medication. It is available only through authorized clinical trials.
Who makes retatrutide?
Eli Lilly, the same company behind tirzepatide products Mounjaro and Zepbound.
If you are choosing an available treatment today, FormBlends offers access to compounded semaglutide and a provider comparison tool.
Related guides
- Semaglutide vs Tirzepatide vs Retatrutide: Single vs Dual vs Triple Agonist — The Full Comparison
- Semaglutide vs Retatrutide: Single vs Triple Agonist Compared
- Semaglutide vs Tirzepatide vs Survodutide: GLP-1 vs Dual GIP/GLP-1 vs Dual Glucagon/GLP-1
- Tirzepatide Vs Retatrutide Next Gen Glp1
Sources
- New England Journal of Medicine, Triple-Hormone-Receptor Agonist Retatrutide for Obesity (phase 2, 2023): https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- FDA prescribing information for tirzepatide (Zepbound): https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →